Published in Pediatr Dermatol on November 01, 1987
Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet (1998) 4.46
Reasons for poor prognosis in British patients with cutaneous malignant melanoma. Br Med J (Clin Res Ed) (1986) 2.49
Severe sunburn and subsequent risk of primary cutaneous malignant melanoma in scotland. Br J Cancer (1982) 2.49
Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet (2001) 2.40
Experience of a public education programme on early detection of cutaneous malignant melanoma. BMJ (1988) 2.36
Malignant melanoma in Scotland 1979-1983. Lancet (1985) 2.30
Circulatory and respiratory changes in response to muscular exercise in man. J Physiol (1928) 2.02
Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol (2000) 1.92
Benign melanocytic naevi as a risk factor for malignant melanoma. Br Med J (Clin Res Ed) (1986) 1.88
Clinical recognition of early invasive malignant melanoma. BMJ (1990) 1.75
The number and distribution of benign pigmented moles (melanocytic naevi) in a healthy British population. Br J Dermatol (1985) 1.75
Norwegian scabies during immunosuppressive therapy. Br Med J (1973) 1.70
Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer (1995) 1.68
Sunbeds in current use in Scotland: a survey of their output and patterns of use. Br J Dermatol (1998) 1.62
Scratching during sleep. Lancet (1973) 1.60
Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol (1991) 1.54
Genetic and environmental influences in the development of multiple primary melanoma. Arch Dermatol (1999) 1.54
Cutaneous malignancy in males treated with photochemotherapy. Lancet (1990) 1.44
Serum lipid elevation during isotretinoin therapy for acne in the west of Scotland. Br J Dermatol (1990) 1.44
Basal cell carcinoma: are early appointments justifiable? Br J Dermatol (2000) 1.41
Fluorescent lights, ultraviolet lamps, and risk of cutaneous melanoma. BMJ (1988) 1.41
Risk of cutaneous melanoma associated with a family history of the disease. The International Melanoma Analysis Group (IMAGE). Int J Cancer (1995) 1.38
Cancer, warts, and sunshine in renal transplant patients. A case-control study. Lancet (1984) 1.34
Early diagnosis of infantile seborrhoeic dermatitis and atopic dermatitis--total and specific IgE levels. Br J Dermatol (1983) 1.24
An aid to the preoperative assessment of pigmented lesions of the skin. Br J Dermatol (1971) 1.21
Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy. Br J Dermatol (2000) 1.17
Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet (2001) 1.17
Management and morbidity of cellulitis of the leg. J R Soc Med (1998) 1.12
Multiple melanoma and atypical melanocytic naevi--evidence of an activated and expanded melanocytic system. Br J Dermatol (1982) 1.12
Utility of adjuvant systemic therapy in melanoma. Ann Oncol (2009) 1.10
Relationships between selected strains of typical and atypical Aeromonas salmonicida, Aeromonas hydrophila, and Haemophilus piscium. Can J Microbiol (1980) 1.09
Early diagnosis of infantile seborrhoeic dermatitis and atopic dermatitis--clinical features. Br J Dermatol (1983) 1.08
Proposed alternative terminology and subclassification of so called "dysplastic naevi". J Clin Pathol (1986) 1.07
Loss of heterozygosity in malignant melanoma at loci on chromosome 11 and 17 implicated in the pathogenesis of other cancers. Genes Chromosomes Cancer (1993) 1.05
Cellular fine structure in the invasive nodules of different histogenetic types of malignant melanoma. Br J Dermatol (1978) 1.03
Initial event in mycosis fungoides of the skin is viral infection of epidermal Langerhans cells. Lancet (1981) 1.03
Validity of the histopathological criteria used for diagnosing dysplastic naevi. An interobserver study by the pathology subgroup of the EORTC Malignant Melanoma Cooperative Group. Eur J Cancer (1993) 1.01
Clinical response of dermatitis herpetiformis skin lesions to a gluten-free diet. Br J Dermatol (1976) 1.01
Heterogeneity of chemosensitivity of metastatic cutaneous melanoma. Anticancer Drugs (1999) 0.97
Synthetic retinoids for acne. Lancet (1980) 0.96
Epidemiology of scabies: the new epidemic. Lancet (1991) 0.95
The pathogenesis of cutaneous malignant melanoma. Br Med J (Clin Res Ed) (1983) 0.94
Localization of elevated transforming growth factor-alpha in psoriatic epidermis. J Invest Dermatol (1990) 0.93
Cutaneous malignant melanoma in Scotland. Br J Cancer (1982) 0.93
Treatment of extensive virus warts with etretinate (Tigason) in a patient with sarcoidosis. Clin Exp Dermatol (1983) 0.92
CDKN2A mutations in Scottish families with cutaneous melanoma: results from 32 newly identified families. Br J Dermatol (2005) 0.92
Blisters, ulceration and autonomic neuropathy in carpal tunnel syndrome. Br J Dermatol (1992) 0.91
Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol (2001) 0.90
The effects of thermal stimulation on the ultrastructure of the human atrichial sweat gland. I. The fundus. Br J Dermatol (1984) 0.90
Quantitation of dendritic cells in normal and abnormal human epidermis using monoclonal antibodies directed against Ia and HTA antigens. J Invest Dermatol (1983) 0.90
Photodynamic therapy for basal cell carcinoma: effect of tumor thickness and duration of photosensitizer application on response. Arch Dermatol (1998) 0.90
Basal cell cytoplasmic autoantibodies in oral lichenoid reactions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1995) 0.89
Melanoma in people aged 65 and over in Scotland, 1979-89. BMJ (1992) 0.89
Further studies of scratching during sleep. Br J Dermatol (1975) 0.88
A case of bullous pemphigoid and figurate erythema in association with metastatic spread of carcinoma. Br J Dermatol (1973) 0.87
Dissociation of HLA heavy chain and light chain (beta 2 microglobulin) expression on the cell surface of cutaneous malignancies. Br J Dermatol (1983) 0.87
Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptase-coupled--polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. Br J Dermatol (2001) 0.87
The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma. Cancer (1985) 0.86
Validation of in vitro chemosensitivity testing in malignant melanoma. Lancet (1983) 0.86
Development of melanocytic nevi in the first three years of life. J Natl Cancer Inst (2000) 0.84
Transepidermal elimination of urate-like crystals: a new perforating disorder? Br J Dermatol (1999) 0.84
Comparison of five antimelanoma antibodies for identification of melanocytic cells on tissue sections in routine dermatopathology. J Am Acad Dermatol (1989) 0.84
Relation between phenotype and banal melanocytic naevi. Br Med J (Clin Res Ed) (1987) 0.84
Multiple primary melanoma: risk factors and prognostic implications. BMJ (1994) 0.84
Benign naevi associated with high risk of melanoma. Lancet (1984) 0.84
Growth hormone levels in psoriasis. Arch Dermatol Res (1983) 0.83
Intestinal permeability and atopic disease. Lancet (1981) 0.83
An evidence base for reconsidering current follow-up guidelines for patients with cutaneous melanoma less than 0.5 mm thick at diagnosis. Br J Dermatol (2008) 0.83
Cerebral metastases of cutaneous melanoma. Br J Cancer (1997) 0.83
Acquired C1-inhibitor deficiency preceding malignant lymphoma by 7 years. J R Soc Med (1991) 0.83
The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma. Br J Cancer (1992) 0.82
Langerhans' cells and subtypes of human papillomavirus in cervical intraepithelial neoplasia. BMJ (1988) 0.82
Studies in cutaneous immunofluorescence. II. Histological and direct immunofluorescence observations in clinically normal skin of patients with rheumatoid arthritis. J Cutan Pathol (1981) 0.82
Human malignant melanoma. Melanosomal polymorphism and the ultrastructural dopa reaction. Br J Dermatol (1978) 0.81
Sun and skin damage. J Intern Med (1993) 0.81
Melphalan concentration and distribution in the tissues of tumour-bearing limbs treated by isolated limb perfusion. Eur J Cancer (1992) 0.81
Keratin expression in normal skin and epidermal neoplasms demonstrated by a panel of monoclonal antibodies. J Cutan Pathol (1992) 0.81
Managing the dysplastic naevus. Lancet (1983) 0.81
Experience with the colony-forming (stem cell) assay of in vitro chemosensitivity in the management of patients with advanced malignant melanoma. Cancer Treat Rep (1984) 0.80
Nine years' experience of BELD combination chemotherapy (bleomycin, vindesine, CCNU and DTIC) for metastatic melanoma. Br J Dermatol (1992) 0.80
The staphylococcal scalded skin syndrome in two elderly immunocompromised patients. Br Med J (Clin Res Ed) (1987) 0.80
Cell-cell and cell-extracellular matrix interactions during melanoma cell invasion and metastasis. Melanoma Res (1993) 0.80
Measurement of daylight UVA in Glasgow. Phys Med Biol (1983) 0.79
Tamoxifen as a single agent for advanced melanoma in postmenopausal women. A phase II study of the EORTC Malignant Melanoma Cooperative Group. Melanoma Res (1992) 0.79
Gamma-interferon in evolving allergic contact dermatitis reactions. Br J Dermatol (1996) 0.79
Effects of trimeprazine and trimipramine on nocturnal scratching in patients with atopic eczema. Arch Dermatol (1979) 0.79
Malignant melanoma of the head and neck in Scotland: an eight-year analysis of trends in prevalence, distribution and prognosis. Q J Med (1987) 0.79
Melanoma cell-derived factor stimulation of fibroblast glycosaminoglycan synthesis--the role of platelet-derived growth factor. Eur J Cancer (1999) 0.78
Comparison between lentigo maligna melanoma and other histogenetic types of malignant melanoma of the head and neck. Scottish Melanoma Group. Br J Cancer (1996) 0.78
The phototumorigenic potential of broad-band (270-350 nm) and narrow-band (311-313 nm) phototherapy sources cannot be predicted by their edematogenic potential in hairless mouse skin. J Invest Dermatol (1995) 0.78
A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb. Eur J Cancer (1996) 0.78
The effects of thermal stimulation on the ultrastructure of the human atrichial sweat gland. II. The duct. Br J Dermatol (1985) 0.78
Modulation of melanoma cell adhesion to basement membrane components by retinoic acid. J Cell Sci (1989) 0.78
A monoclonal antibody technique to demonstrate an increase in Langerhans cells in cutaneous lesions of mycosis fungoides. Clin Exp Dermatol (1982) 0.78
The effect of oral retinoid therapy on the normal human immune system. Br J Dermatol (1988) 0.78
Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol (2000) 0.78
A comparison of dosimetric methods in isolated limb perfusion with melphalan for malignant melanoma of the lower extremity. Eur J Cancer (1996) 0.78
Angioma serpiginosum: a simulator of purpura. Postgrad Med J (1991) 0.78
Effect of maintenance chemotherapy in childhood on numbers of melanocytic naevi. BMJ (1992) 0.78
A study of HLA antigen distribution in families with atopic dermatitis. Allergy (1979) 0.78